Literature DB >> 31865260

The impact of cannabis access laws on opioid prescribing.

Benjamin J McMichael1, R Lawrence Van Horn2, W Kip Viscusi3.   

Abstract

While recent research has shown that cannabis access laws can reduce the use of prescription opioids, the effect of these laws on opioid use is not well understood for all dimensions of use and for the general United States population. Analyzing a dataset of over 1.5 billion individual opioid prescriptions between 2011 and 2018, which were aggregated to the individual provider-year level, we find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 11.8 and 4.2 percent, respectively. These laws also reduce the total days' supply of opioids prescribed, the total number of patients receiving opioids, and the probability a provider prescribes any opioids net of any offsetting effects. Additionally, we find consistent evidence that cannabis access laws have different effects across types of providers, physician specialties, and payers.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Marijuana; Opioids

Mesh:

Substances:

Year:  2019        PMID: 31865260     DOI: 10.1016/j.jhealeco.2019.102273

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  11 in total

1.  Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis.

Authors:  George Dranitsaris; Carlo DeAngelis; Blake Pearson; Laura McDermott; Bernd Pohlmann-Eden
Journal:  Appl Health Econ Health Policy       Date:  2021-01-25       Impact factor: 2.561

2.  The state of the evidence on the association between state cannabis laws and opioid-related outcomes: A review.

Authors:  Kayla N Tormohlen; Mark C Bicket; Sarah White; Colleen L Barry; Elizabeth A Stuart; Lainie Rutkow; Emma E McGinty
Journal:  Curr Addict Rep       Date:  2021-09-28

3.  Trends in Alcohol, Cigarette, E-Cigarette, and Nonprescribed Pain Reliever Use Among Young Adults in Washington State After Legalization of Nonmedical Cannabis.

Authors:  Charles B Fleming; Jason J Ramirez; Isaac C Rhew; Brittney A Hultgren; Koren G Hanson; Mary E Larimer; Julia A Dilley; Jason R Kilmer; Katarina Guttmannova
Journal:  J Adolesc Health       Date:  2022-05-09       Impact factor: 7.830

4.  The impact of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance.

Authors:  Jiebing Wen; Hefei Wen; J S Butler; Jeffery C Talbert
Journal:  Health Econ       Date:  2021-02-23       Impact factor: 3.046

5.  Demand curve analysis of marijuana use among persons living with HIV.

Authors:  Mark K Greenwald; Siri S Sarvepalli; Jonathan A Cohn; Leslie H Lundahl
Journal:  Drug Alcohol Depend       Date:  2021-01-12       Impact factor: 4.492

6.  Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011.

Authors:  June H Kim; Silvia S Martins; Dvora Shmulewitz; Deborah Hasin
Journal:  Int J Drug Policy       Date:  2021-09-26

7.  Choosing Between a Rock and the Pot Place.

Authors:  Ariana M Nelson
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-12

8.  Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado.

Authors:  Amalie K Kropp Lopez; Stephanie D Nichols; Daniel Y Chung; Daniel E Kaufman; Kenneth L McCall; Brian J Piper
Journal:  Int J Environ Res Public Health       Date:  2020-05-07       Impact factor: 3.390

9.  So near yet so far: why won't the UK prescribe medical cannabis?

Authors:  David Nutt; Steve Bazire; Lawrence D Phillips; Anne Katrin Schlag
Journal:  BMJ Open       Date:  2020-09-21       Impact factor: 2.692

10.  Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.

Authors:  Cerina Lee; Mu Lin; Karen J B Martins; Jason R B Dyck; Scott Klarenbach; Lawrence Richer; Ed Jess; John G Hanlon; Elaine Hyshka; Dean T Eurich
Journal:  BMC Public Health       Date:  2021-05-01       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.